Check 35,000+ stocks against 26 valuation models and 37 quality factors

JBM (Healthcare) Limited (2161) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of JBM (Healthcare) Limited HK$5.15, price HK$1.62, upside +217.9%, quality 78 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN KYG1090B1077

JH Thin data Sep 24, 2026

JBM (Healthcare) Limited

2161 · HK

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value HK$5.15 · Strongly undervalued (+217.9%)

✓Quality 78/100

✓Healthy Growth (revenue 5y +16.0 %/yr)

✓Highly profitable · 24.1% net margin (TTM)

✓Low debt · generates free cash flow

✓10.6% dividend yield · Sustainable

✓Ranks above peers (14/14)

✓Wide moat 82/100

!Evidence only low, so the estimate is less certain

!Weak on future: 28 out of 100

26 models, one by oneBear HK$3.32 to bull HK$8.09 Growth analysisrevenue history, year by year Quality 78/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch JBM (Healthcare) Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$0.4875 – HK$3.12 · fair‑value band HK$3.32 – HK$8.09 · the HK$1.62 price screens below the HK$5.15 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow JBM (Healthcare) in your weekly email

Every Wednesday you see whether JBM (Healthcare) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JBM (Healthcare) Limited, an investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, Singapore, and internationally. It operates through Branded Medicines, Proprietary Chinese Medicines, and Health and Wellness Products segments. The Branded Medicines segment develops, manufactures, and distributes branded medicines with chemical compounds as active ingredients. The Proprietary Chinese Medicines segment develops, manufactures, and distributes registered Chinese medicines composed of Chinese herbal medicines. The Health and Wellness Products segment distributes and sells supplements, medical consumables, and other non-pharmaceutical products for the general health and wellness of consumers. The company also offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter medicines, and CCMG products. It is also involved in the manufactures, trading, wholesaling, and retailing of Chinese medicines; trading of medical supplies and pharmaceutical products; and sale of healthcare and herbal products. The company was incorporated in 2020 and is headquartered in Kwun Tong, Hong Kong.

Stock analysis

JBM (Healthcare) Limited (2161) currently trades at HK$1.62, while our model-based Fair Value estimate is HK$5.15, implying the stock looks roughly 68.5% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$6.22 per share, and 23 of the 26 models we run sit above the HK$1.62 price.

Bear case: the Asset-Based group reads lowest at HK$0.8800, and 3 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$3.32 (bear) to HK$8.09 (bull), the price of HK$1.62 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 78/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

JBM (Healthcare) Limited reported revenue of HK$835M in FY2026 versus HK$406M in FY2022, a compound +19.7%/yr. Reported net income was HK$201M in FY2026, compounding +69.1%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.

Key figures

Market cap HK$1.7B (≈ $211M) · P/E ratio 8.1 · P/S ratio 1.95 · EPS (TTM) HK$0.1100 · Dividend yield 10.6% · Net margin 24.1% · Return on equity 18.3% · Return on assets (EBIT) 10.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 218%, 2161 screens cheaper than that median.

Fair Value models

Bear HK$3.32 Fair Value HK$5.15 Bull HK$8.09

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$2.91 HK$4.52 HK$8.17 78

Growth DCF HK$2.79 HK$4.72 HK$7.40 77

Residual Income HK$1.29 HK$1.66 HK$2.41 75

All 26 models by family

DCF Models

FCF DCF HK$2.91 HK$4.52 HK$8.17 78

Owner Earnings HK$3.24 HK$5.83 HK$10.06 74

5Y Revenue Exit HK$2.52 HK$4.43 HK$7.20 71

5Y EBITDA Exit HK$3.46 HK$6.55 HK$10.79 73

5Y P/E Exit HK$3.53 HK$6.76 HK$10.74 69

10Y Revenue Exit HK$2.56 HK$4.36 HK$7.13 65

10Y EBITDA Exit HK$3.18 HK$5.77 HK$10.18 66

10Y P/E Exit HK$3.22 HK$5.89 HK$10.14 61

Earnings-Based

Graham-Dodd HK$1.67 HK$10.36 HK$14.46 63

Lynch FV HK$2.98 HK$4.25 HK$5.53 61

PEG = 1.0 HK$2.98 HK$4.25 HK$5.53 57

EPV HK$1.99 HK$2.21 HK$2.39 74

Dividend Discount

Gordon GGM HK$0.6700 HK$1.12 HK$1.45 68

DDM Multi-Stage HK$0.6700 HK$1.06 HK$1.20 67

Multiples

P/E Multiple HK$4.05 HK$5.40 HK$6.75 63

P/S Multiple HK$2.67 HK$3.56 HK$4.45 58

P/B Multiple HK$3.13 HK$4.17 HK$5.21 55

EV/EBIT HK$4.09 HK$5.41 HK$6.72 66

EV/EBITDA HK$4.07 HK$5.37 HK$6.68 67

EV/Revenue HK$2.28 HK$3.20 HK$4.12 54

Asset-Based

NCAV (Graham) HK$0.6600 HK$0.8800 HK$1.32 54

Growth DCF

Growth DCF HK$2.79 HK$4.72 HK$7.40 77

Rev-Margin DCF HK$2.52 HK$4.39 HK$7.05 71

Economic Profit

Residual Income HK$1.29 HK$1.66 HK$2.41 75

ROIC Compounder HK$2.24 HK$2.85 HK$3.61 72

Growth Earnings

Growth-Adj P/E HK$4.36 HK$6.22 HK$8.09 67

Open the full fair value analysis →

Notify me when 2161 reaches fair value

Put 2161 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 78/100

Of which business quality 74 · Market factors (momentum, volatility) 29

Profitability 62

Margins and returns on capital today

Quality Growth 44

Are margins and returns improving?

Cashflow 81

Earnings quality: real cash, not paper profit

Fin. Strength 82

Balance sheet, leverage, solvency risk

Investment 81

Disciplined investing over empire-building

Low Volatility 85

Calm price path (market factor)

Momentum 9

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 92

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+6.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+16.0%

Start year 2021 (pandemic)

Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.5%

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+83.5%

Earnings growth per share plus dividend.

Earnings per share, growth per year+72.9%

Dividend (yield on the price)10.6%

Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 30%

2026 sits 67% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−6.8%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about −8.7% a year for the price.

Watch 2161, get fair value alerts →

Compare JBM (Healthcare) Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 13/13 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 78 · Top 25%

Fair Value upside +200.0% · Top 25%

Profitability

Return on equity (TTM) 18.3% · Top 25%

Return on assets 10.0% · Top 25%

Net margin (TTM) 24.1% · Top 25%

Operating margin (TTM) 29.2% · Top 25%

Growth and dividend

Revenue growth 5.6% · Above median

Dividend yield (TTM) 10.6% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 8.1× · Cheapest 25%

P/B 1.53× · Cheaper than median

P/S (TTM) 1.98× · Cheaper than median

P/FCF 8.0× · Cheapest 25%

EV/EBITDA 5.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 17

FUTURE (revenue growth)28 · sector 24

PAST (return on equity)73 · sector 27

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)100 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

JBM (Healthcare) Limited · Fair Value
HK$5.15 +69%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/2161" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">JBM (Healthcare) Limited · Fair Value</span><br><b style="font-size:20px">HK$5.15</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+69%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "JBM (Healthcare) Limited Fair Value". https://www.fairvalue-calculator.com/stock/2161

Frequently asked questions

Is JBM (Healthcare) Limited (2161) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of HK$5.15 versus a price of HK$1.62, about +218% upside (undervalued).

What is the fair value of 2161?

Our model-based fair value for JBM (Healthcare) Limited is HK$5.15 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$1.62.

What is the quality score of 2161?

JBM (Healthcare) Limited has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for JBM (Healthcare) Limited (2161)?

Our model-based price target is the fair value of HK$5.15 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario HK$3.32, optimistic scenario HK$8.09. It is a calculation from audited fundamentals, not an analyst target.

What is the JBM (Healthcare) Limited stock forecast for 2026?

Our models put fair value at HK$5.15, about +218% upside versus a price of HK$1.62 (undervalued). Cautious scenario HK$3.32, optimistic scenario HK$8.09. The calculation is refreshed regularly with new filings.

What is the revenue of JBM (Healthcare) Limited (2161)?

JBM (Healthcare) Limited reported trailing-twelve-month revenue of about HK$835M (latest available figure, as of Sep 24, 2026).

Does JBM (Healthcare) Limited pay a dividend?

JBM (Healthcare) Limited currently shows a dividend yield of about 10.56% relative to its recent price (as of Sep 24, 2026).

What growth is priced into JBM (Healthcare) Limited (2161)?

For today's price to be fair in a discounted-cash-flow model, JBM (Healthcare) Limited would have to grow free cash flow by -6.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.0 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 2161 use?

Our models discount JBM (Healthcare) Limited at 11.8 %: a base by market capitalisation (micro), damped by beta 0.21, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For JBM (Healthcare) Limited that is -6.8 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.

How much growth has JBM (Healthcare) Limited (2161) delivered so far?

Over the past 5 years revenue at JBM (Healthcare) Limited grew +16.0 % a year. The price currently implies -6.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of JBM (Healthcare) Limited (2161) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into JBM (Healthcare) Limited (-6.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of JBM (Healthcare) Limited (2161)?

The free-cash-flow yield on the price is 15.57 %: that much free cash flow JBM (Healthcare) Limited produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of JBM (Healthcare) Limited (2161)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JBM (Healthcare) Limited it is HK$5.15 per share (as of Sep 24, 2026), against a price of HK$1.62. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is JBM (Healthcare) Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 2161 trades below its calculated fair value: price HK$1.62, fair value HK$5.15, a gap of about +218% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 2161?

No. The price is what the market pays today (HK$1.62); the fair value is what the company's own numbers justify (HK$5.15). For JBM (Healthcare) Limited the two are HK$3.53 per share apart. That gap is exactly why we show both numbers side by side.

How much is JBM (Healthcare) Limited worth?

The market values JBM (Healthcare) Limited at about HK$1.7B (market capitalisation, as of Sep 24, 2026). Per share that is HK$1.62; our models calculate a fair value of HK$5.15 per share.

What do the bullish and bearish scenarios say about 2161?

Our models span a range for JBM (Healthcare) Limited: cautious scenario HK$3.32, base HK$5.15, optimistic HK$8.09 per share (as of Sep 24, 2026, price HK$1.62). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 2161?

JBM (Healthcare) Limited trades at a price-to-earnings ratio of 8.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$5.15 is built from several models across several years. Other multiples: P/B 1.5, P/S 2.0, EV/EBITDA 5.1.

How solid is the balance sheet of JBM (Healthcare) Limited (2161)?

Balance-sheet figures for JBM (Healthcare) Limited (as of Sep 24, 2026): return on equity 18.3%. They feed the Quality Score of 78/100, which measures business quality independently of the share price.

How far is 2161 from its 52-week high?

JBM (Healthcare) Limited trades at HK$1.62, about 45% below its 52-week high of HK$2.92 and at the low of HK$1.62 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$5.15 is for.

Which stocks are comparable to JBM (Healthcare) Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is JBM (Healthcare) Limited stock attractive at the current price?

The data as of Sep 24, 2026: price HK$1.62, calculated fair value HK$5.15 (+218%), Quality Score 78/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 2161 calculated?

We run JBM (Healthcare) Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$5.15, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. JBM (Healthcare) Limited currently trades 69 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of JBM (Healthcare) Limited (2161)?

The closing price on Oct 2, 2026 was HK$1.62. Our model-based fair value is HK$5.15, about +218% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with JBM (Healthcare) Limited right now?

The rarer combination: high quality (78/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (HK$3.32). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$3.32 to HK$8.09) leaves room in how you read the outcome.

Key figures of JBM (Healthcare) Limited

How large is the market capitalisation of JBM (Healthcare) Limited (2161)?

The market capitalisation of JBM (Healthcare) Limited is HK$1.7B (≈ $211M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of JBM (Healthcare) Limited (2161)?

The price-to-sales ratio of JBM (Healthcare) Limited is 1.95 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of JBM (Healthcare) Limited (2161)?

Earnings per share at JBM (Healthcare) Limited are HK$0.1100 (price ÷ EPS = P/E 8.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of JBM (Healthcare) Limited (2161)?

The dividend yield of JBM (Healthcare) Limited is 10.6% (payout 155%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of JBM (Healthcare) Limited (2161)?

The net margin of JBM (Healthcare) Limited is 24.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of JBM (Healthcare) Limited (2161)?

The return on equity (ROE) of JBM (Healthcare) Limited is 18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of JBM (Healthcare) Limited (2161)?

On an EBIT basis the return on assets of JBM (Healthcare) Limited is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of JBM (Healthcare) Limited (2161)?

The operating margin of JBM (Healthcare) Limited is 29.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at JBM (Healthcare) Limited (2161)?

Revenue at JBM (Healthcare) Limited is growing +5.6% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at JBM (Healthcare) Limited (2161)?

Earnings per share at JBM (Healthcare) Limited are growing −2.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does JBM (Healthcare) Limited (2161) carry?

The net debt of JBM (Healthcare) Limited is HK$274M (fiscal year 2026, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch JBM (Healthcare) Limited in the live analysis

One click puts JBM (Healthcare) Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.